來自CDC網站，注意下表最後兩行。
https://wwwnc.cdc.gov/eid/article/27/3/20-4543_article
Table 2
Positivity of antibodies to severe acute respiratory syndrome coronavirus 2 in 58 asymptomatic or mildly symptomatic patients at 8 mo after infection, South Korea*
| Characteristic | Anti-N pan-Ig ECLIA, no. (%)† | Anti-N IgG ELISA, no. (%)‡ | Anti-S IgG ELISA, no. (%)§ | Anti-S1 IgG ELISA, no. (%)¶ | sVNT, no. (%)# |
|---|---|---|---|---|---|
| Total
|
53/58 (91.4)
|
15/58 (25.9)
|
50/58 (86.2)
|
40/58 (69.0)
|
31/58 (53.4)
|
| Sex | |||||
| M | 21/23 (91.3) | 1/23 (4.3) | 17/23 (73.9) | 11/23 (47.8) | 7/23 (30.4) |
| F
|
32/35 (91.4)
|
14/35 (40.0)**
|
33/35 (94.3)††
|
29/35 (82.9)**
|
24/35 (68.6)**
|
| Age, y | |||||
| <30 | 35/38 (92.1) | 5/38 (13.2) | 33/38 (86.8) | 25/38 (65.8) | 19/38 (50.0) |
| >30
|
18/20 (90.0)
|
10/20 (50.0)**
|
17/20 (85.0)
|
15/20 (75.0)
|
12/20 (60.0)
|
| Duration of PCR positivity | |||||
| <14 d | 3/6 (50.0) | 3/6 (50.0) | 4/6 (66.7) | 3/6 (50.0) | 2/6 (33.3) |
| >14 d
|
48/50 (96.0)**
|
10/50 (20.0)
|
44/50 (88.0)
|
36/50 (72.0)
|
27/50 (54.0)
|
| Disease severity | |||||
| Asymptomatic | 7/7 (100) | 0/7 (0) | 5/7 (71.4) | 4/7 (57.1) | 4/7 (57.1) |
| Mildly symptomatic | 46/51 (90.2) | 15/51 (29.4) | 45/51 (88.2) | 36/51 (70.6) | 27/51 (52.9) |
*Anti-N, antinucleocapsid; anti-S, antispike; anti-S1, antispike subunit; ECLIA, electrochemiluminescence immunoassay; pan-Ig, panimmunoglobulin; sVNT, surrogate virus neutralization test.?†Roche Diagnostics (https://diagnostics.roche.com). ?‡Epitope Diagnostics (https://www.epitopediagnostics.com).?§InBios International (https://www.inbios.com).?¶Euroimmun (https://www.euroimmune.com).?#GenScript (https://www.genscript.com).?**p<0.01.?††p<0.05.
Conclusions
we confirmed that rates of antibody positivity according to 3 commercial kits was still high at 8 months after infection, even in asymptomatic or mildly symptomatic participants (69.0%–91.4%).
